{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:25:26Z","timestamp":1790799926674,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2684,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/annonc\/mds358","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T08:24:49Z","timestamp":1347870289000},"page":"x128-x131","source":"Crossref","is-referenced-by-count":21,"special_numbering":"S10","title":["How to approach patients in relapse"],"prefix":"10.1016","volume":"23","author":[{"given":"E.","family":"Pujade-Lauraine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mds358_bb0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Gynecologic Cancer InterGroup. Clinical trials in recurrent ovrian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mds358_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds358_bb0020","article-title":"Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study","volume":"21","author":"Pujade-Lauraine","year":"2002","journal-title":"Proc am Soc Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mds358_bb0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst."},{"issue":"9747","key":"10.1093\/annonc\/mds358_bb0030","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1093\/annonc\/mds358_bb0035","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft Gynaekologische Onkologie (aGO) DESKTOP OVaR trial","volume":"13","author":"Harter","year":"2006","journal-title":"ann Surg Oncol"},{"issue":"1","key":"10.1093\/annonc\/mds358_bb0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mds358_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. a project of the aGO Kommission OVaR, aGO study group, NOGGO, aGO-austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mds358_bb0050","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/IGC.0b013e3181e82a7f","article-title":"Clinical utility of positron emission tomography\/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal Ca-125 levels","volume":"20","author":"Bhosale","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl","key":"10.1093\/annonc\/mds358_bb0055","volume":"30","author":"Sehouli","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mds358_bb0060","doi-asserted-by":"crossref","first-page":"viii61","DOI":"10.1093\/annonc\/mdr518","article-title":"Update of randomized trials in recurrent disease","volume":"22","author":"Pujade-Lauraine","year":"2011","journal-title":"ann Oncol."},{"issue":"20","key":"10.1093\/annonc\/mds358_bb0065","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol."},{"issue":"19","key":"10.1093\/annonc\/mds358_bb0070","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mds358_bb0075","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEaNS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"aghajanian","year":"2012","journal-title":"J Clin Oncol."},{"issue":"suppl","key":"10.1093\/annonc\/mds358_bb0080","article-title":"aURELIa: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mds358_bb0085","article-title":"Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study","volume":"30","author":"Oza","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds358_bb0090","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase ii study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds358_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdh025","article-title":"International topotecan study group. Long-term survival in a phase iii, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma","volume":"15","author":"Ten Bokkel Huinink","year":"2004","journal-title":"ann Oncol"},{"key":"10.1093\/annonc\/mds358_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Doxil Study 30\u201349 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol."},{"key":"10.1093\/annonc\/mds358_bb0105","first-page":"203a","article-title":"a phase iii study of Doxil\/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer [abstract 808]","volume":"21","author":"O'Byrne","year":"2002","journal-title":"Proc am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mds358_bb0110","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"26","author":"Mutch","year":"2008","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mds358_bb0115","first-page":"2811","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"25","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1093\/annonc\/mds358_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ijgc-00009577-200409001-00005","article-title":"Topotecan versus treosulphan in early recurrent ovarian cancer after primary platinum\/paclitaxel chemotherapy. a prospective randomized phase III trial of the aGO ovarian cancer study group [abstract 005]","volume":"14","author":"Meier","year":"2004","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"10.1093\/annonc\/mds358_bb0125","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.ejca.2009.05.016","article-title":"Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer","volume":"45","author":"Vergote","year":"2009","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419417948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419417948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/suppl_10\/x128\/6686761\/mds358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:45:36Z","timestamp":1744152336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419417948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":24,"alternative-id":["S0923753419417948"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds358","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}